Safety, Pharmacokinetics, and Activity of AT-752, a Novel Nucleotide Prodrug with Pan-Serotype Activity against Dengue Virus: A Phase 2, Randomized, Double-Blind Study
The American Journal of Tropical Medicine and Hygiene · 2025
DOI: 10.4269/ajtmh.24-0696 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The American Journal of Tropical Medicine and Hygiene, 2025. Verfasst von Arantxa Horga und 11 weiteren Autor:innen. Beteiligte Einrichtung: Atea Pharmaceuticals, Inc., Boston, Massachusetts. Hauptthemen laut MEDLINE: Dengue Virus, Dengue, Antiviral Agents, Prodrugs. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
AT-752 is a novel guanosine nucleotide prodrug inhibitor with pan-serotype antiviral activity against dengue virus. In this phase 2, randomized, double-blind, placebo-controlled study, we evaluated the activity, safety, and pharmacokinetics of oral AT-752 (750 mg thrice daily for 5 days) compared with a placebo in 21 adults with confirmed dengue infection. The primary endpoint was the change from baseline in viral load via reverse transcription quantitative polymerase chain reaction testing, with assessments performed daily on Days 1–8, 14, and 28. The primary endpoint was nonevaluable because many patients presented late during the course of disease, with low baseline viremia levels precluding accurate quantification at subsequent timepoints. In the as-treated population (patients with assessment at baseline and at each post-baseline timepoint), the numerical mean reduction (versus baseline) in viral load on Day 4 was greater in the AT-752 group than the placebo group ( P = 0.0022). The median time to a sustained resolution of fever (the major clinical sign of dengue) was 4 days in the AT-752 group compared with >5 days in the placebo group; the reduction in oral temperature at the Day 4 timepoint was greater in the AT-752 group (treatment difference: 0.84°C; P = 0.0322). There was a trend toward faster platelet recovery in the AT-752 group compared with the placebo group, and proportionally fewer patients in the AT-752 group underwent hospitalization for disease progression (one patient in each group). AT-752 exhibited favorable safety and tolerability; the majority of adverse events were mild or moderate, and Grade 3 or 4 adverse events occurred at similar rates in both groups. These data support the further evaluation of AT-752 in treating dengue in future clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Atea Pharmaceuticals, Inc., Boston, Massachusetts.
- Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
- Down Town Hospital, Guwahati, India.
Zitieren
APA
Horga, A., Teixeira, M. M., Borthakur, S., Lynch, S., Chin, J., Ishak, L., Zhou, X. J., Pietropaolo, K., Belanger, B., Lei, Y., Huang, Q., & Hammond, J. (2025). Safety, Pharmacokinetics, and Activity of AT-752, a Novel Nucleotide Prodrug with Pan-Serotype Activity against Dengue Virus: A Phase 2, Randomized, Double-Blind Study. The American Journal of Tropical Medicine and Hygiene. https://doi.org/10.4269/ajtmh.24-0696
Vancouver
Horga A, Teixeira MM, Borthakur S, Lynch S, Chin J, Ishak L, et al. Safety, Pharmacokinetics, and Activity of AT-752, a Novel Nucleotide Prodrug with Pan-Serotype Activity against Dengue Virus: A Phase 2, Randomized, Double-Blind Study. The American Journal of Tropical Medicine and Hygiene. 2025. doi:10.4269/ajtmh.24-0696
BibTeX
@article{Horga2025,
author = {Horga, Arantxa and Teixeira, Mauro M and Borthakur, Swapnav and Lynch, Shannan and Chin, Janice and Ishak, Laura and Zhou, Xiao-Jian and Pietropaolo, Keith and Belanger, Bruce and Lei, Yang and Huang, Qi and Hammond, Janet},
title = {Safety, Pharmacokinetics, and Activity of AT-752, a Novel Nucleotide Prodrug with Pan-Serotype Activity against Dengue Virus: A Phase 2, Randomized, Double-Blind Study},
journal = {The American Journal of Tropical Medicine and Hygiene},
year = {2025},
doi = {10.4269/ajtmh.24-0696}
}
EUVIMED